Anumana Acquires NeuTrace to Advance Electrophysiology Deep Learning

Artificial intelligence (AI)-driven health tech firm Anumana (a portfolio company of nference) has acquired NeuTrace, a company focused on novel in-procedure AI applications for electrophysiology (EP).
 
The deal includes the NeuTrace EP Data Biome platform and portfolio of AI-enabled EP software applications in development. As part of the transaction, nference acquired rights to the Data Biome platform for uses outside of the cardiovascular field.
 
The acquisition dives Anumana a combined development capability powered by nference’s nSights real world evidence generation platform that can integrate a patient’s entire electronic medical record (EMR) with corresponding electrocardiograms (ECG) taken from the surface of the body and cardiac electrograms (EGM) taken from within the heart.
 
“Anumana is pioneering new ground in cardiology AI software solutions that span the entire patient journey,” David McMullin, chief business officer of Anumana told the press. “With its deep learning models detecting patterns too subtle for the human eye to see, from undiagnosed disease in routine ECGs to real-time EGM signals during critical EP procedures, Anumana is on a mission to improve patient care by unlocking the electrical language of the heart as never before.”
 
“We’ve been impressed by the complementary depth, breadth, and strength of the Anumana and nference teams and are excited by the transformative potential of the combined organizations,” said Srijoy Mahapatra, M.D., president and chief operating officer of NeuTrace. “Combining the power of NeuTrace’s EP Data Biome with EMR and other data modalities of nference’s nSights platform has the potential to unlock game-changing AI applications in early cardiovascular disease detection, rhythm management, and EP procedure safety, efficacy, and effectiveness, for improved long-term outcomes.”